FAP and pancreatic adenocarcinoma: The first-in-human study of [177Lu]Lu-FAP-2286 for peptide-targeted radionuclide therapy (PTRT) was carried out on 11 patients with advanced adenocarcinomas of the pancreas, breast, rectum, or ovary with prior confirmation of uptake on [68Ga]Ga-FAP-2286 or [68Ga]Ga-FAPI-04 PET/CT.